Sorrento Adds ADC Development Capabilities With Concortis Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
The San Diego biotech hopes to develop antibody-drug conjugate therapies for cancer that will offer more specific targeting and more stable drug-to-antibody ratios, compared to ADCs now on the market. The acquisition is just the latest in a busy stretch of deal-making for Sorrento.